Novartis announces new leader of Pharmaceuticals Business Unit
June 07 2019 - 1:00AM
Novartis International AG / Novartis announces new leader of
Pharmaceuticals Business Unit . Processed and transmitted by West
Corporation. The issuer is solely responsible for the content of
this announcement.
-
Marie-France Tschudin, an
experienced Novartis leader, appointed to President, Novartis
Pharmaceuticals
Basel, June 7, 2019 - Novartis announced
today that Marie-France Tschudin, currently President, Advanced
Accelerator Applications (AAA), a Novartis company, has been
appointed President, Novartis Pharmaceuticals. She will report to
Vas Narasimhan, CEO Novartis, and will join the Executive Committee
with immediate effect. Marie-France Tschudin succeeds Paul Hudson
who will be leaving Novartis to take the CEO position of a
multinational pharmaceuticals company.
Vas Narasimhan, CEO Novartis, said: "I am pleased that Marie-France
Tschudin is ready to take over from Paul Hudson to further grow the
business and lead the expected upcoming launches of our
transformative medicines. Marie-France has a strong record of
accomplishments in driving commercial excellence and a culture of
inclusiveness and integrity founded on her exemplary commitment to
patients and customers. She has always been highly respected by
people working with her and will bring new and diverse perspectives
to our executive leadership team. I would like to thank Paul for
his exceptional leadership in positioning our pharmaceuticals
business for strong future growth. He also established a new
culture of commercial excellence, integrity and nurtured a strong,
diverse talent pool."
Regarding her appointment, Marie-France Tschudin said: "I'm honored
and excited to be given the opportunity to lead and further develop
one of the greatest businesses in our industry. I would like to
thank Paul for his leadership and his focus on people and I wish
him continued success going forward. I'm excited to deliver my part
in reimagining medicine for as many people as possible together
with our associates at Novartis."
Marie-France Tschudin has more than 25 years of broad,
multi-national experience in the pharmaceuticals and biotech
industry. She joined Novartis in January 2017. As a member of
the Novartis Pharmaceuticals Executive Committee and Head of
Novartis Pharmaceuticals, Region Europe she successfully grew the
largest regional business within Novartis across countries,
therapeutic areas and products to over USD 8 Billion in sales by
the end of 2018. She also built a diverse leadership team, managed
the entire pharmaceuticals portfolio and oversaw the preparations
for our potential blockbuster launches in Europe. Before
joining Novartis, Marie-France spent 10 years at Celgene in a
variety of leadership and general management positions and led
their Hematology-Oncology business for Europe, Middle East and
Africa from 2014 to 2016.
Marie-France Tschudin is a Swiss citizen. She speaks six languages,
graduated from Georgetown University, Washington D.C. and holds a
Master in Business Administration from the Institute for Management
Development (IMD), Lausanne.
Disclaimer
This press release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. Forward-looking statements can generally be identified
by words such as "will," "to further grow," "expected," "upcoming,"
"launches," "commitment," "future growth," "excited," "to deliver,"
"potential," or similar expressions, or by express or implied
discussions regarding the launch of potential new products,
potential new indications for existing products, or regarding
potential future sales or earnings of the Pharmaceuticals business
unit or the Novartis Group. You should not place undue reliance on
these statements. Such forward looking statements are based on our
current beliefs and expectations regarding future events, and are
subject to significant known and unknown risks and uncertainties.
Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may
vary materially from those set forth in the forward looking
statements. There can be no guarantee that the investigational or
approved products described in this press release will be submitted
or approved for sale or for any additional indications or labeling
in any market or at any particular time. Nor can there be any
guarantee that the Pharmaceuticals business unit or Novartis will
be commercially successful in the future, or achieve any particular
financial results. In particular, our expectations could be
affected by, among other things: regulatory actions or delays or
government regulation generally; global trends toward health care
cost containment, including government, payor and general public
pricing and reimbursement pressures; uncertainties regarding actual
or potential legal proceedings; the uncertainties inherent in the
research and development of new healthcare products; our ability to
obtain or maintain proprietary intellectual property protection on
key products; safety, quality or manufacturing issues; general
political and economic conditions, including uncertainties
regarding the effects of ongoing instability in various parts of
the world; uncertainties regarding future global exchange rates;
uncertainties regarding future demand for our products; and
uncertainties regarding potential significant breaches of data
security or data privacy, or disruptions of our information
technology systems; and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and
Exchange Commission. Novartis is providing the information in this
press release as of this date and does not undertake any obligation
to update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
About Novartis
Novartis is reimagining medicine to improve and extend people's
lives. As a leading global medicines company, we use innovative
science and digital technologies to create transformative
treatments in areas of great medical need. In our quest to find new
medicines, we consistently rank among the world's top companies
investing in research and development. Novartis products reach more
than 750 million people globally and we are finding innovative ways
to expand access to our latest treatments. About 105 000 people of
more than 140 nationalities work at Novartis around the world. Find
out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please
contact media.relations@novartis.com
# # #
Novartis Media
Relations
E-mail: media.relations@novartis.com
Antonio
Ligi
Novartis Global External Communications
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
antonio.ligi@novartis.com
|
Eric
Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com |
Novartis Investor
Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central |
|
North
America |
|
Samir
Shah |
+41 61
324 7944 |
Richard
Pulik |
+1 862
778 3275 |
Pierre-Michel Bringer |
+41 61
324 1065 |
Cory
Twining |
+1 862
778 3258 |
Thomas
Hungerbuehler |
+41 61
324 8425 |
|
|
Isabella
Zinck |
+41 61
324 7188 |
|
|
Media release (PDF)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novartis International AG via Globenewswire
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Apr 2023 to Apr 2024